One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan

BACKGROUND: Long duration trial data for two-dose COVID-19 vaccines primary series’ are uncommon due to unblinding and additional doses. We report one-year follow-up results from a phase 1/2 trial of AZD1222 (ChAdOx1 nCoV-19) in Japan. METHODS: Adults (n = 256) seronegative for severe acute respirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Kensuke, Nascimento, Maria-Claudia, Asano, Michiko, Hirata, Hajime, Itoh, Yohji, Kelly, Elizabeth J., Matsui, Akiko, Olsson, Urban, Shoemaker, Kathryn, Green, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237326/
https://www.ncbi.nlm.nih.gov/pubmed/37271703
http://dx.doi.org/10.1016/j.vaccine.2023.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237326/
https://www.ncbi.nlm.nih.gov/pubmed/37271703
http://dx.doi.org/10.1016/j.vaccine.2023.05.015

Ejemplares similares